Abstract
Recombinant antihypertensive peptide multimer (AHPM-2, 8kDa/68AA), a new designed polypeptide with potential antihypertensive effect in vivo, is composed of 15 low-molecular-weight antihypertensive peptides tandemly linked up according to the restriction sites of gastrointestinal proteases. After gene optimization, the DNA fragment encoding AHPM-2 was chemically synthesized, cloned into the pET32a, and successfully expressed in E.coli, above 90% in a soluble form. After chromatographic purification, the expressed fusion protein Trx-AHPM-2 was subject to the simulated gastrointestinal digestion, and the hydrolysate showed potent ACE inhibitory activity with an IC50 value of 4.5±0.3 ìg ml-1. The active fragments from the AHPM-2 were identified by UPLC-MS/MS. This method will be useful in obtaining an appreciable quantity of recombinant AHP at low cost, and the intact AHPM-2 is expected to be developed into functional food for preventing hypertension as well as for therapeutic.
Keywords: Antihypertensive peptide, antihypertensive peptide multimer, design, expression, Escherichia coliAntihypertensive peptide, antihypertensive peptide multimer, design, expression, Escherichia coli
Protein & Peptide Letters
Title: Cloning, Soluble Expression, and Production of Recombinant Antihypertensive Peptide Multimer (AHPM-2) in Escherichia coli for Bioactivity Identification
Volume: 18 Issue: 7
Author(s): Shengqi Rao, Zhenzhen Xu, Yujie Su, Junhua Li, Jun Sun and Yanjun Yang
Affiliation:
Keywords: Antihypertensive peptide, antihypertensive peptide multimer, design, expression, Escherichia coliAntihypertensive peptide, antihypertensive peptide multimer, design, expression, Escherichia coli
Abstract: Recombinant antihypertensive peptide multimer (AHPM-2, 8kDa/68AA), a new designed polypeptide with potential antihypertensive effect in vivo, is composed of 15 low-molecular-weight antihypertensive peptides tandemly linked up according to the restriction sites of gastrointestinal proteases. After gene optimization, the DNA fragment encoding AHPM-2 was chemically synthesized, cloned into the pET32a, and successfully expressed in E.coli, above 90% in a soluble form. After chromatographic purification, the expressed fusion protein Trx-AHPM-2 was subject to the simulated gastrointestinal digestion, and the hydrolysate showed potent ACE inhibitory activity with an IC50 value of 4.5±0.3 ìg ml-1. The active fragments from the AHPM-2 were identified by UPLC-MS/MS. This method will be useful in obtaining an appreciable quantity of recombinant AHP at low cost, and the intact AHPM-2 is expected to be developed into functional food for preventing hypertension as well as for therapeutic.
Export Options
About this article
Cite this article as:
Rao Shengqi, Xu Zhenzhen, Su Yujie, Li Junhua, Sun Jun and Yang Yanjun, Cloning, Soluble Expression, and Production of Recombinant Antihypertensive Peptide Multimer (AHPM-2) in Escherichia coli for Bioactivity Identification, Protein & Peptide Letters 2011; 18 (7) . https://dx.doi.org/10.2174/092986611795446067
DOI https://dx.doi.org/10.2174/092986611795446067 |
Print ISSN 0929-8665 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5305 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Role of Redox Homeostasis and Inflammation in the Pathogenesis of Pulmonary Arterial Hypertension
Current Medicinal Chemistry The Metabolic Treatment of Patients with Coronary Artery Disease: Effects on Quality of Life and Effort Angina
Current Pharmaceutical Design Validated Spectrodensitometric Method for Simultaneous Estimation of Sofosbuvir, Ribavirin and Saxagliptin in their Pure and Pharmaceutical Dosage Forms
Current Pharmaceutical Analysis Medical Therapy of Aortic Aneurysms: A Pathophysiology-Based Approach
Current Vascular Pharmacology Carbon Monoxide, A Two-Face for the Protection of the Liver
Current Pharmaceutical Biotechnology Future Prospects in Anti-Platelet Therapy: A Review of Potential P2Y12 and Thrombin Receptor Antagonists
Recent Patents on Cardiovascular Drug Discovery Cardiovascular Effects of Liraglutide
Current Hypertension Reviews Current Treatment Options for HCC: From Pharmacokinetics to Efficacy and Adverse Events in Liver Cirrhosis
Current Drug Metabolism Evidence of Lifestyle Modification in the Management of Hypercholesterolemia
Current Cardiology Reviews Celiac Disease: An Emerging Epidemic
Current Nutrition & Food Science Diagnosis, Treatment, and New Developments in Preeclampsia
Current Women`s Health Reviews Evaluation of Risk Factors Associated with Diabetic Foot Ulcers in Saudi Arabia
Current Diabetes Reviews A Gastroretentive Drug Delivery System of Lisinopril Imbibed on Isabgol- Husk
Current Drug Delivery Total Bakkenolides Protects Neurons Against Cerebral Ischemic Injury Through Inhibition of Nuclear Factor-κB Activation
CNS & Neurological Disorders - Drug Targets Renal Denervation Therapy: Can it Contribute to Better Blood Pressure Control in Hypertension?
Current Vascular Pharmacology Sedation and Analgesia in Pediatric Intensive Care
Current Drug Targets Nitric Oxide in Cancer Therapeutics: Interaction with Cytotoxic Chemotherapy
Current Pharmaceutical Design Re-Centering Diabetes Care through Community: The iHealthSpace Example
Current Diabetes Reviews Non-Invasive Assessment of Atherosclerosis Risk
Current Drug Targets - Cardiovascular & Hematological Disorders Stability-indicating UPLC-PDA Method for Ambrisentan Tablets and Identification of a Main Degradation Product by UPLC-MS/MS
Current Pharmaceutical Analysis